Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

Ipilimumab induced autoantibodies in a fifth of melanoma patients. Patients who developed autoantibodies, especially thyroid autoantibodies, experienced more irAEs and had a survival and response benefit, suggesting that breaking of B-cell tolerance could indicate therapy toxicity and efficacy. Immune-checkpoint inhibitors (ICIs) activate the immune system to assault cancer cells in a manner that is not antigen specific. We hypothesized that tolerance may also be broken to autoantigens, resulting in autoantibody formation, which could be associated with immune-related adverse events (irAEs) and antitumor efficacy. Twenty-three common clinical autoantibodies in pre- and posttreatment sera from 133 ipilimumab-treated melanoma patients were determined, and their development linked to the occurrence of irAEs, best overall response, and survival. Autoantibodies developed in 19.2% (19/99) of patients who were autoantibody-negative pretreatment. A nonsignificant association was observed between development of any autoantibodies and any irAEs [OR, 2.92; 95% confidence interval (CI) 0.85–10.01]. Patients with antithyroid antibodies after ipilimumab had significantly more thyroid dysfunction under subsequent anti–PD-1 therapy: 7/11 (54.6%) patients with antithyroid antibodies after ipilimumab developed thyroid dysfunction under anti–PD1 versus 7/49 (14.3%) patients without antibodies (OR, 9.96; 95% CI, 1.94–51.1). Patients who developed autoantibodies showed a trend for better survival (HR for all-cause death: 0.66; 95% CI, 0.34–1.26) and therapy response (OR, 2.64; 95% CI, 0.85–8.16). We conclude that autoantibodies develop under ipilimumab treatment and could be a potential marker of ICI toxicity and efficacy.

[1]  J. Schachter,et al.  Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. , 2018, Autoimmunity reviews.

[2]  M. Akiyama,et al.  Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study , 2018, Journal of the Endocrine Society.

[3]  A. Ribas,et al.  Endocrinopathies with use of cancer immunotherapies , 2018, Clinical endocrinology.

[4]  A. Ravaud,et al.  Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study , 2017, Annals of the rheumatic diseases.

[5]  F. Guaraldi,et al.  Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution , 2018, Journal of Endocrinological Investigation.

[6]  J. Wolchok,et al.  Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Schraml,et al.  Pembrolizumab‐induced hepatitis: diagnosis and treatment , 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[8]  C. Garbe,et al.  Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. , 2017, European journal of cancer.

[9]  E. Plimack,et al.  Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. , 2017, Cancer treatment reviews.

[10]  J. Larkin,et al.  Thyroid abnormalities following the use of cytotoxic T‐lymphocyte antigen‐4 and programmed death receptor protein‐1 inhibitors in the treatment of melanoma , 2017, Clinical endocrinology.

[11]  D. Schadendorf,et al.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. Velcheti,et al.  Correction: Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity , 2017, RMD Open.

[13]  C. Rudin,et al.  Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Ami A. Shah,et al.  Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab , 2016, Annals of the rheumatic diseases.

[15]  M. Faham,et al.  Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. , 2017, Cancer research.

[16]  M. Faham,et al.  Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients. , 2016 .

[17]  T. Barnetche,et al.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis , 2015, BMC Medicine.

[18]  Paulo Luiz Carvalho Francescantônio,et al.  Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015 , 2015, Front. Immunol..

[19]  Amitabh Srivastava,et al.  Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases , 2015, The American journal of surgical pathology.

[20]  Ritwik Pandey,et al.  Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy , 2015, BMJ Case Reports.

[21]  N. Urgancı,et al.  Antithyroid Antibodies and Thyroid Function in Pediatric Patients with Celiac Disease , 2015, International journal of endocrinology.

[22]  A. Araszkiewicz,et al.  Prevalence of anti-thyroid peroxidase in adults with type 1 diabetes participating in Poznań Prospective Study. , 2015 .

[23]  S. H. van der Burg,et al.  Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response , 2014, Science Translational Medicine.

[24]  Ryan Emerson,et al.  CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire , 2014, Clinical Cancer Research.

[25]  J. Anaya,et al.  Autoimmune Thyroid Disease in Rheumatoid Arthritis: A Global Perspective , 2012, Arthritis.

[26]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[27]  J. Kirkwood,et al.  Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.

[28]  S. Aamdal,et al.  Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. , 2009, Journal of the National Cancer Institute.

[29]  I. Yavaşoğlu,et al.  Rheumatoid Arthritis and Anti-Thyroid Antibodies , 2009, Autoimmunity.

[30]  A. Filipowicz-Sosnowska,et al.  Prevalence of thyroid diseases and antithyroid antibodies in women with rheumatoid arthritis. , 2009, Polskie Archiwum Medycyny Wewnetrznej.

[31]  N. Mousavinasab,et al.  Thyroid function and anti-thyroid antibodies in Iranian patients with type 1 diabetes mellitus: influences of age and sex. , 2008, Iranian journal of allergy, asthma, and immunology.

[32]  M. Turiel,et al.  Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: Prevalence and clinical value , 2008, Autoimmunity.

[33]  K. Zaletel,et al.  Thyroid autoantibody production is influenced by exon 1 and promoter CTLA‐4 polymorphisms in patients with Hashimoto's thyroiditis , 2006, International journal of immunogenetics.

[34]  G. Barbesino,et al.  CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. , 2001, The Journal of clinical endocrinology and metabolism.

[35]  G. Brabant,et al.  Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Monson,et al.  Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha. , 1991, British Journal of Cancer.

[37]  M. Atkins,et al.  Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. , 1988, The New England journal of medicine.

[38]  M. Feldmann,et al.  ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY , 1983, The Lancet.